Published in J Clin Oncol on April 14, 2008
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res (2009) 4.02
Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98
Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer (2013) 3.75
Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol (2014) 2.73
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol (2011) 1.99
Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer (2009) 1.99
Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys (2011) 1.74
Validation of a web-based predictive nomogram for ipsilateral breast tumor recurrence after breast conserving therapy. J Clin Oncol (2010) 1.59
What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol (2009) 1.52
Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT. Eur J Nucl Med Mol Imaging (2014) 1.48
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer (2012) 1.48
Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer (2011) 1.48
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat (2012) 1.39
Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int J Clin Exp Pathol (2010) 1.24
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist (2011) 1.22
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res (2012) 1.16
Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer (2011) 1.15
The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One (2011) 1.14
Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter? Cancer (2010) 1.14
Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres. Cell Cycle (2012) 1.14
Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys (2011) 1.07
The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set. PLoS One (2015) 1.06
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2012) 1.05
Past, present, and future challenges in breast cancer treatment. J Clin Oncol (2014) 1.04
Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol (2011) 1.03
Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol (2011) 1.02
Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Ann Surg Oncol (2014) 1.01
Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res (2011) 1.01
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat (2012) 0.99
Human breast cancer associated fibroblasts exhibit subtype specific gene expression profiles. BMC Med Genomics (2012) 0.98
Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg (2011) 0.97
Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer (2009) 0.96
Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? Neoplasia (2009) 0.95
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer Epidemiol Biomarkers Prev (2014) 0.95
Patient demographic and tumor characteristics influencing oncologist follow-up frequency in older breast cancer survivors. Ann Surg Oncol (2013) 0.95
Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Hum Pathol (2011) 0.94
Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1-T2 breast cancer and 1-3 positive lymph nodes. Ann Surg Oncol (2014) 0.94
Effects of age on the detection and management of breast cancer. Cancers (Basel) (2015) 0.94
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res (2012) 0.93
Intraoperative radiotherapy for early breast cancer: do health professionals choose convenience or risk? Radiat Oncol (2014) 0.92
Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol (2010) 0.92
The management of early-stage and metastatic triple-negative breast cancer: a review. Hematol Oncol Clin North Am (2013) 0.92
Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget (2014) 0.91
Co-overexpression of GEP100 and AMAP1 proteins correlates with rapid local recurrence after breast conservative therapy. PLoS One (2013) 0.91
Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg (2012) 0.90
Management options in triple-negative breast cancer. Breast Cancer (Auckl) (2011) 0.90
Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Br J Radiol (2013) 0.90
Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines. Breast Cancer (Auckl) (2011) 0.89
Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol (2011) 0.89
External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study. Int J Radiat Oncol Biol Phys (2012) 0.89
Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys (2011) 0.89
Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells. Breast Cancer Res (2014) 0.89
Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtype. J Breast Cancer (2011) 0.87
Which patients might benefit from postmastectomy radiotherapy in breast cancer patients with t1-2 tumor and 1-3 axillary lymph nodes metastasis? Cancer Res Treat (2013) 0.87
Comparison of accelerated partial breast irradiation via multicatheter interstitial brachytherapy versus whole breast radiation. Radiat Oncol (2012) 0.87
Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer (2013) 0.87
Breast cancer in young women: special considerations in multidisciplinary care. J Multidiscip Healthc (2014) 0.87
DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol (2015) 0.85
Breast cancer subtypes and survival in chinese women with operable primary breast cancer. Chin J Cancer Res (2011) 0.85
Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy. J Korean Med Sci (2010) 0.84
Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico. Cancer Med (2013) 0.84
Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. Br J Cancer (2015) 0.84
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis. Cell Div (2013) 0.83
An institutional retrospective analysis of 93 patients with brain metastases from breast cancer: treatment outcomes, diagnosis-specific prognostic factors. Int J Mol Sci (2012) 0.83
Optimizing surgical margins in breast conservation. Int J Surg Oncol (2012) 0.83
Genomics and challenges toward personalized breast cancer local control. J Clin Oncol (2008) 0.82
Utilization and Outcomes of Breast Brachytherapy in Younger Women. Int J Radiat Oncol Biol Phys (2015) 0.82
Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol (2013) 0.82
The implications of breast cancer molecular phenotype for radiation oncology. Front Oncol (2011) 0.82
Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PLoS One (2014) 0.82
Identifying and targeting tumor-initiating cells in the treatment of breast cancer. Endocr Relat Cancer (2015) 0.81
Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer. J Surg Res (2013) 0.81
The evolution of the locoregional therapy of breast cancer. Oncologist (2011) 0.81
Risk factors for distant metastasis as a primary site of treatment failure in early-stage breast cancer. Chonnam Med J (2014) 0.80
Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. Springerplus (2015) 0.80
Safe negative margin width in breast conservative therapy: results from a population with a high percentage of negative prognostic factors. World J Surg (2014) 0.80
Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry. J Breast Cancer (2015) 0.80
Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. Breast J (2014) 0.80
Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer. J Breast Cancer (2013) 0.80
Does applicability domain exist in microarray-based genomic research? PLoS One (2010) 0.80
Prognostic factors affecting postmastectomy locoregional recurrence in patients with early breast cancer: are intrinsic subtypes effective? World J Surg (2011) 0.80
Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. Breast Cancer Res Treat (2016) 0.80
Oxidative stress-mediated apoptosis induced by ethanolic mango seed extract in cultured estrogen receptor positive breast cancer MCF-7 cells. Int J Mol Sci (2015) 0.79
Dual FGF-2 and intergrin alpha5beta1 signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy. Cancer Microenviron (2009) 0.79
HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy. World J Surg Oncol (2014) 0.79
Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer. Cancer (2016) 0.79
Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer. J Natl Cancer Inst (2014) 0.79
Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification. PLoS One (2012) 0.79
Androgen Receptor: A Complex Therapeutic Target for Breast Cancer. Cancers (Basel) (2016) 0.79
Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol (2014) 0.79
The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. Sci Rep (2017) 0.78
Intraoperative Boost Radiotherapy during Targeted Oncoplastic Breast Surgery: Overview and Single Center Experiences. Int J Breast Cancer (2014) 0.78
Prognostic significance of breast cancer subtype and p53 overexpression in patients with locally advanced or high-risk breast cancer treated using upfront modified radical mastectomy with or without post-mastectomy radiation therapy. Int J Clin Oncol (2011) 0.78
Detection of prognostic factors in metastatic breast cancer. J Res Med Sci (2013) 0.78
A phase I study of intraoperative radiotherapy for early breast cancer in Japan. World J Surg (2009) 0.78
High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. Carcinogenesis (2016) 0.78
Predictive Factors for Non-Sentinel Lymph Node Metastasis in the Case of Positive Sentinel Lymph Node Metastasis in Two or Fewer Nodes in Breast Cancer. J Clin Med Res (2015) 0.78
Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis. Breast Care (Basel) (2015) 0.77
Ductal carcinoma in situ of the breast. N Engl J Med (2004) 6.63
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
CNS metastases in breast cancer. J Clin Oncol (2004) 4.42
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys (2006) 4.22
A failure analysis of invasive breast cancer: most deaths from disease occur in women not regularly screened. Cancer (2013) 4.21
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009) 3.91
Local therapy and survival in breast cancer. N Engl J Med (2007) 3.33
Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol (2006) 3.33
Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys (2002) 3.21
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol (2011) 3.17
Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. Int J Radiat Oncol Biol Phys (2002) 3.15
Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst (2011) 2.77
Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol (2008) 2.72
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med (2009) 2.39
Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol (2014) 2.38
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA (2010) 2.16
Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin (2002) 2.07
Accelerated partial breast irradiation with low-dose-rate interstitial implant brachytherapy after wide local excision: 12-year outcomes from a prospective trial. Int J Radiat Oncol Biol Phys (2011) 2.06
Effective local therapy and long-term survival in breast cancer. Oncology (Williston Park) (2009) 2.06
Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review. J Clin Oncol (2008) 2.04
Irradiation in early-stage breast cancer: conventional whole-breast, accelerated partial-breast, and accelerated whole-breast strategies compared. Oncology (Williston Park) (2012) 2.04
Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med (2009) 2.04
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol (2011) 1.99
Analysis of data errors in clinical research databases. AMIA Annu Symp Proc (2008) 1.99
Occult nipple involvement in breast cancer: clinicopathologic findings in 316 consecutive mastectomy specimens. J Clin Oncol (2009) 1.99
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
Nipple Loss following Nipple-Sparing Mastectomy. Plast Reconstr Surg (2016) 1.95
Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline concordance. J Natl Cancer Inst (2011) 1.92
Surgical margins in lumpectomy for breast cancer--bigger is not better. N Engl J Med (2012) 1.91
Offering participants results of a clinical trial: sharing results of a negative study. Lancet (2005) 1.90
Proton beams to replace photon beams in radical dose treatments. Acta Oncol (2003) 1.87
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol (2012) 1.87
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. Phys Med (2007) 1.81
Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys (2010) 1.76
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg (2009) 1.76
Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.75
Mammographic screening: patterns of use and estimated impact on breast carcinoma survival. Cancer (2004) 1.66
Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiother Oncol (2010) 1.65
Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. Int J Radiat Oncol Biol Phys (2013) 1.62
Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol (2011) 1.60
Validation of a web-based predictive nomogram for ipsilateral breast tumor recurrence after breast conserving therapy. J Clin Oncol (2010) 1.59
Permanent alopecia after cranial irradiation: dose-response relationship. Int J Radiat Oncol Biol Phys (2004) 1.58
Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys (2003) 1.57
Quantification of mediastinal and hilar lymph node movement using four-dimensional computed tomography scan: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys (2007) 1.56
Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys (2009) 1.55
Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys (2009) 1.55
Beyond biologics: absorbable mesh as a low-cost, low-complication sling for implant-based breast reconstruction. Plast Reconstr Surg (2014) 1.53
From physical dose constraints to equivalent uniform dose constraints in inverse radiotherapy planning. Med Phys (2003) 1.52
Prospective trial of real-time electronic surveillance to expedite early care of severe sepsis. Ann Emerg Med (2011) 1.51
Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer (2010) 1.47
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract (2014) 1.47
The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM. Med Phys (2012) 1.46
Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol (2014) 1.46
Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res (2007) 1.44
Can axillary dissection be avoided in patients with sentinel lymph node metastasis? J Surg Oncol (2006) 1.43
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Ann Surg Oncol (2015) 1.43
Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer. N Engl J Med (2007) 1.43
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol (2008) 1.42
Breast reconstruction following nipple-sparing mastectomy: predictors of complications, reconstruction outcomes, and 5-year trends. Plast Reconstr Surg (2014) 1.39
Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavity. Int J Radiat Oncol Biol Phys (2007) 1.37
Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res (2009) 1.37
Brachytherapy for accelerated partial-breast irradiation: a rapidly emerging technology in breast cancer care. J Clin Oncol (2010) 1.33
The feasibility of using natural language processing to extract clinical information from breast pathology reports. J Pathol Inform (2012) 1.30
Evidence for multiple interspecific hybridization in Saccharomyces sensu stricto species. FEMS Yeast Res (2002) 1.29
Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.28
Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol (2014) 1.28
Incidence of major corrective surgery after post-mastectomy breast reconstruction and radiation therapy. Breast J (2008) 1.23
Standardized method for quantification of developing lymphedema in patients treated for breast cancer. Int J Radiat Oncol Biol Phys (2010) 1.21
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer (2011) 1.20